However, in our previous study [ 7 ] we observed a clear trend towards an improved graft survival in patients, who received a bortezomib-based treatment over a rituximab-based treatment, so that we deliberately decided to treat all upcoming patients with a bortezomib-based protocol and refrained from further trials on rituximab-based treatment in order not to expose patients to a (in our opinion) potentially higher risk of graft loss.
← all excerpts
Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
1
—
—